Randox diabetes testing portfolio
Type 2 diabetes mellitus (T2DM) now attains the status of global pandemic, spreading from developed to developing countries. The epidemiological trends indicate that the prevalence will continue to increase dramatically. The World Health Organization estimates diabetes to be the seventh global leading cause of death, accounting for 1.6 million deaths in 2016. Randox is committed to advancing diabetes testing, including the associated complications. Randox offers a comprehensive range of high quality reagents ranging from diabetes risk assessment, diagnosis and monitoring of diabetes, and monitoring of associated complications. The Randox diabetes portfolio covers the full spectrum of clinical biochemistry laboratory testing requirements including several superior performance and unique assays. Applications are available detailing instrument-specific settings for a wide range of clinical chemistry analysers.